Trials / Completed
CompletedNCT00542724
An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 1 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 462 (actual)
- Sponsor
- Biodel · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to demonstrate equivalent blood glucose control in patients with type 1 diabetes mellitus with insulin VIAject™ and regular human insulin as prandial insulin and to demonstrate an equivalent safety profile for VIAject™ in comparison to regular human insulin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VIAject™ | Dosage as individually required |
| DRUG | Regular Human Insulin | Dosage as individually required |
Timeline
- Start date
- 2006-09-01
- Primary completion
- 2008-07-01
- First posted
- 2007-10-11
- Last updated
- 2015-08-03
Source: ClinicalTrials.gov record NCT00542724. Inclusion in this directory is not an endorsement.